NCT05240976View on ClinicalTrials.gov

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

March 31, 2027

Conditions
Schizophrenia
Interventions
DRUG

NMDAE plus AIFA

Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of ultra-resistant schizophrenia.

DRUG

NMDAE plus Placebo Cap

Use of an NMDA enhancer plus placebo as a comparator

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

National Health Research Institutes, Taiwan

OTHER

lead

China Medical University Hospital

OTHER